However, varying sensitivity to lenvatinib has been reported among patients with HCC [4], and several mechanisms of resistance to lenvatinib have been identified, such as enhanced epidermal growth factor receptor (EGFR) signaling and Wnt/β-catenin signaling [5]. Here, EGFR is linked to hepatocellular carcinoma.